用于反义寡核苷酸和小干扰RNA递送的纳米技术与控释系统。
Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.
作者信息
Fattal Elias, Barratt Gillian
机构信息
Univ Paris Sud 11, UMR 8612, Châtenay-Malabry, F-92290, France.
出版信息
Br J Pharmacol. 2009 May;157(2):179-94. doi: 10.1111/j.1476-5381.2009.00148.x. Epub 2009 Apr 2.
Abstract
Antisense oligonucleotides and small interfering RNA have enormous potential for the treatment of a number of diseases, including cancer. However, several impediments to their widespread use as drugs still have to be overcome: in particular their lack of stability in physiological fluids and their poor penetration into cells. Association with or encapsulation within nano- and microsized drug delivery systems could help to solve these problems. In this review, we describe the progress that has been made using delivery systems composed of natural or synthetic polymers in the form of complexes, nanoparticles or microparticles.
摘要
反义寡核苷酸和小干扰RNA在治疗包括癌症在内的多种疾病方面具有巨大潜力。然而，要将它们广泛用作药物仍需克服若干障碍：特别是它们在生理流体中缺乏稳定性以及难以穿透细胞。与纳米和微米级药物递送系统结合或封装在其中可能有助于解决这些问题。在本综述中，我们描述了使用由天然或合成聚合物以复合物、纳米颗粒或微粒形式组成的递送系统所取得的进展。
相似文献
1
Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.
Br J Pharmacol. 2009 May;157(2):179-94. doi: 10.1111/j.1476-5381.2009.00148.x. Epub 2009 Apr 2.
2
Innovative nanotechnologies for the delivery of oligonucleotides and siRNA.
Biomed Pharmacother. 2006 Nov;60(9):607-20. doi: 10.1016/j.biopha.2006.07.093. Epub 2006 Aug 31.
3
State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.
Int J Pharm. 2008 Dec 8;364(2):237-48. doi: 10.1016/j.ijpharm.2008.06.011. Epub 2008 Jun 19.
4
Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System.
Mol Pharm. 2021 Apr 5;18(4):1491-1506. doi: 10.1021/acs.molpharmaceut.0c01238. Epub 2021 Mar 18.
5
Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA.
Eur J Pharm Biopharm. 2009 Mar;71(3):490-504. doi: 10.1016/j.ejpb.2008.09.024. Epub 2008 Nov 1.
6
Oral delivery of siRNA and antisense oligonucleotides.
J Drug Target. 2009 Aug;17(7):491-5. doi: 10.1080/10611860903057674.
7
Biological barriers to therapy with antisense and siRNA oligonucleotides.
Mol Pharm. 2009 May-Jun;6(3):686-95. doi: 10.1021/mp900093r.
8
Dermal/transdermal delivery of small interfering RNA and antisense oligonucleotides- advances and hurdles.
Biomed Pharmacother. 2017 Mar;87:311-320. doi: 10.1016/j.biopha.2016.12.118. Epub 2017 Jan 5.
9
Lipid conjugated oligonucleotides: a useful strategy for delivery.
Bioconjug Chem. 2012 Jun 20;23(6):1091-104. doi: 10.1021/bc200422w. Epub 2012 Mar 15.
10
Hyaluronan-based delivery of therapeutic oligonucleotides for treatment of human diseases.
Expert Opin Drug Deliv. 2019 Jun;16(6):621-637. doi: 10.1080/17425247.2019.1617693. Epub 2019 May 20.
引用本文的文献
1
Exploring the potential of nanomedicine for gene therapy across the physicochemical and cellular barriers.
Funct Integr Genomics. 2024 Sep 28;24(5):177. doi: 10.1007/s10142-024-01459-z.
2
Development and application of ribonucleic acid therapy strategies against COVID-19.
Int J Biol Sci. 2022 Aug 1;18(13):5070-5085. doi: 10.7150/ijbs.72706. eCollection 2022.
3
Systematic Combination of Oligonucleotides and Synthetic Polymers for Advanced Therapeutic Applications.
Macromol Res. 2021;29(10):665-680. doi: 10.1007/s13233-021-9093-5. Epub 2021 Nov 5.
4
The development and improvement of ribonucleic acid therapy strategies.
Mol Ther Nucleic Acids. 2021 Dec 3;26:997-1013. doi: 10.1016/j.omtn.2021.09.002. Epub 2021 Sep 14.
5
Molecular and Coarse-Grained Modeling to Characterize and Optimize Dendrimer-Based Nanocarriers for Short Interfering RNA Delivery.
ACS Omega. 2020 Feb 7;5(6):2978-2986. doi: 10.1021/acsomega.9b03908. eCollection 2020 Feb 18.
6
Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment.
Int J Mol Sci. 2019 Aug 29;20(17):4224. doi: 10.3390/ijms20174224.
7
Encapsulation of nor-β-lapachone into poly(d,l)-lactide--glycolide (PLGA) microcapsules: full characterization, computational details and cytotoxic activity against human cancer cell lines.
Medchemcomm. 2017 Sep 7;8(10):1993-2002. doi: 10.1039/c7md00196g. eCollection 2017 Oct 1.
8
Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation.
Molecules. 2017 Oct 13;22(10):1724. doi: 10.3390/molecules22101724.
9
Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides.
Drug Deliv. 2017 Nov;24(1):1249-1261. doi: 10.1080/10717544.2017.1370511.
10
Anti-microRNA-21/221 and microRNA-199a transfected by ultrasound microbubbles induces the apoptosis of human hepatoma HepG2 cells.
Oncol Lett. 2017 May;13(5):3669-3675. doi: 10.3892/ol.2017.5910. Epub 2017 Mar 24.
本文引用的文献
1
Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response.
Pharm Res. 2008 Dec;25(12):2972-82. doi: 10.1007/s11095-008-9693-1. Epub 2008 Aug 16.
2
Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles.
J Neuroimmunol. 2008 Mar;195(1-2):21-7. doi: 10.1016/j.jneuroim.2007.12.005. Epub 2008 Mar 4.
3
siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma.
Nucleic Acids Res. 2008 Jan;36(1):e2. doi: 10.1093/nar/gkm1094. Epub 2007 Dec 13.
4
Impact of PAMAM G2 and G6 dendrimers on bovine serum albumin (fatty acids free and loaded with different fatty acids).
Colloids Surf B Biointerfaces. 2008 May 1;63(1):27-33. doi: 10.1016/j.colsurfb.2007.10.020. Epub 2007 Nov 4.
5
Importance of size-to-charge ratio in construction of stable and uniform nanoscale RNA/dendrimer complexes.
Org Biomol Chem. 2007 Nov 21;5(22):3674-81. doi: 10.1039/b711242d. Epub 2007 Oct 2.
6
Delivery of siRNA from lyophilized polymeric surfaces.
Biomaterials. 2008 Feb;29(4):506-12. doi: 10.1016/j.biomaterials.2007.10.003. Epub 2007 Oct 24.
7
Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles.
Biotechnol Bioeng. 2008 Mar 1;99(4):975-85. doi: 10.1002/bit.21668.
8
Tumor-targeted delivery of siRNA by self-assembled nanoparticles.
Mol Ther. 2008 Jan;16(1):163-9. doi: 10.1038/sj.mt.6300323. Epub 2007 Oct 9.
9
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging.
Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15549-54. doi: 10.1073/pnas.0707461104. Epub 2007 Sep 17.
10
Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system.
Cancer Res. 2007 Sep 1;67(17):8156-63. doi: 10.1158/0008-5472.CAN-06-4762.
Zotero 插件